BACKGROUND/OBJECTIVES: Thoracic radiotherapy (RT) is associated with acute toxicities, including oesophagitis, which can have an impact on nutritional intake and subsequently lead to malnutrition. This study aimed to identify RT dosimetric factors associated with ⩾ 5% weight loss in patients receiving treatment for non-small-cell lung cancer (NSCLC). METHODS: Radiation dose data to the oesophagus (including mean, maximum dose and oesophageal length) were retrospectively analysed for a cohort of 54 NSCLC patients treated with concurrent chemoradiotherapy between 2004 and 2006. Weight change was calculated using the lowest weight during the 90 days from RT commencement compared with the start of RT. RESULTS: Four patients for whom weight was not available at the start or end of treatment were excluded, leaving 50 patients for analysis. The prevalence of significant weight loss during the 90 days from RT commencement was 22% (median weight loss = 9.1%, range = 5.9-22.1). Dosimetric factors significantly associated with ⩾ 5% weight loss were maximum dose to the oesophagus (P = 0.046), absolute oesophageal length receiving 40 Gy (odds ratio (OR) = 1.18, P = 0.04), 50 Gy (OR = 1.20, P = 0.02) and 60 Gy (OR = 1.32, P = 0.005) to the partial circumference, relative oesophageal length receiving 50 Gy (OR = 1.03, P = 0.03) and 60 Gy (OR = 1.07, P = 0.005) to the partial circumference. CONCLUSIONS: Multiple dosimetric factors were associated with significant weight loss. Of these factors, absolute and relative length of the oesophagus receiving 60 Gy to the partial circumference were more strongly related. Understanding the dosimetric factors associated with weight loss may aid early identification and intervention in patients at nutritional risk.
INTRODUCTION
Acute radiation oesophagitis is a common toxicity associated with thoracic radiotherapy (RT) during treatment for lung cancer. 1 Concurrent chemoradiotherapy (cCRT), which has become the standard of care for the treatment of inoperable stage III nonsmall-cell lung cancer (NSCLC), is associated with a higher incidence of severe acute oesophageal toxicity than thoracic RT alone. 2, 3 The clinical manifestation of acute oesophagitis as dysphagia or odynophagia (pain on swallowing) can adversely affect the ability to achieve adequate nutritional intake and consequently lead to loss of weight and malnutrition. 4 A large body of evidence demonstrates the negative impact of malnutrition on patient and clinical outcomes during cancer treatment. Malnutrition or loss of weight is associated with reduced survival, 5, 6 increased health-care utilisation, 6 ,7 reduced functional capacity 8, 9 and reduced treatment completion. 6, 10 In the absence of an assessment of malnutrition, weight loss is often used as an objective surrogate measure of nutritional status. 10, 11 In clinical practice, understanding the factors that are predictive of the development of loss of weight, and therefore malnutrition, allows clinicians to identify those patients who are at high nutritional risk and subsequently direct resources towards timely nutritional intervention before the onset of malnutrition.
Numerous studies have been undertaken in the head and neck cancer population to identify patient-and treatment-related factors, including tumour site and stage, associated with weight loss or the requirement for enteral feeding. 12 In addition, RT dosimetric factors to swallowing structures such as the pharyngeal constrictor muscles and upper oesophageal sphincter that are associated with poorer swallowing outcomes have been investigated in head and neck cancer patients. [12] [13] [14] [15] [16] In lung cancer patients receiving RT, the treatment and RT dosimetric factors associated with the development of acute and late oesophageal toxicity have been the subject of a number of studies. 3, [17] [18] [19] A systematic review has been undertaken on the dose-volume parameters that predicted oesophagitis in patients receiving thoracic RT. This review revealed that the parameters that had been well studied and that had the highest levels of association were mean oesophageal dose, and the volume of the oesophagus receiving 20, 30, 40, 50 and 60 Gy. 1 Oesophageal toxicity is potentially dose limiting because of the associated impact on fluid and nutritional intake. Although the dosimetric factors associated with oesophageal toxicity have been well studied, no studies to date have investigated dosimetric factors associated with clinically significant weight loss during RT treatment for lung cancer. The aim of this study was to identify the prevalence of clinically significant weight loss (⩾5%) during the 90 days from commencement of RT in patients receiving treatment for NSCLC and associated RT dosimetric factors.
MATERIALS AND METHODS Patients
This study was a secondary analysis of data collected as part of a cohort study examining rates of acute and late oesophagitis and associated dosimetric factors in NSCLC patients. The details of this study are described in Everitt el al. (unpublished data, refer to Supplementary Material). The cohort comprised 54 patients with NSCLC treated at a tertiary cancer centre between October 2004 and June 2006. Patients were eligible for inclusion if they had a pathologically confirmed NSCLC; received treatment with concurrent chemotherapy and three-dimensional-conformal highdose palliative or radical RT; availability of oesophageal dose-volume histograms and adequate patient records documenting the assessment of acute oesophagitis and body weight. Patients were excluded if they had received previous thoracic RT; had treatment with RT alone; a treatment break of more than 5 days during RT; an inconsistent dose of radiation per fraction during the course of radiation or treatment with a hyperfractionated radiation schedule. Approval was received from the centre's ethics committee to conduct the study.
Treatment
Patients were treated in accordance with the institutional clinical protocol for high-dose palliative or radical RT. RT target delineation was performed using Focal (CMS Inc., St Louis, MO, USA). Three-dimensional conformal RT plans were calculated on Xio (CMS Inc.) using 6 MV photons and a fast superposition algorithm and delivered on a Varian linear accelerator (Varian Medical Systems Inc., Palo Alto, CA, USA). Concurrent chemotherapy regimens were as follows: patients treated with 30 Gy over 3 weeks received weekly gemcitabine; patients treated with 40 Gy over 4 weeks received cisplatin and vinorelbine weekly; patients treated with 45 Gy over 3 weeks received carboplatin and paclitaxel weekly; patients treated with 50 Gy over 5 weeks or 60 Gy over 6 weeks received carboplatin in weeks 1 and 6, or carboplatin weekly, or carboplatin and paclitaxel weekly ± daily gefitinib.
Demographic data
Demographic (age and gender) and clinical (disease stage, dose of RT and type of chemotherapy administered) data were collected as part of the original cohort study.
Weight
Weight at the commencement and end of RT were also collected as part of the original cohort study. These times were defined as any time within the first or final 5 days of RT, respectively. Additional data on weight measured within the acute toxicity period (up to 90 days from the commencement of RT) were extracted from each patient's electronic medical record. The percentage change in weight was calculated using the lowest available weight at any time in the 90 days from the start of RT, compared with weight at the commencement of RT. Patients were grouped into those who had lost ⩾ 5% body weight and those who lost less than 5% body weight during the 90 days from commencement of RT. Defining the groups by loss of 5% body weight is reflective of clinically significant weight loss and an indicator of malnutrition. 20 
Dosimetric analysis
Dosimetry analysis was undertaken as part of the original study. The outer muscular border of the oesophagus was contoured on CT-derived images from the inferior level of the larynx to the gastro-oesophageal junction. Radiation therapy dose-volume histograms were used to determine the maximum and mean oesophageal doses; the volume of the oesophagus; the absolute oesophageal volume receiving 20, 30, 40, 50 and 60 Gy; and the absolute oesophageal length receiving 20, 30, 40, 50 and 60 Gy to the whole and partial circumference. The relative oesophageal volume and relative oesophageal length were calculated as a percentage of the total volume and total length of the oesophagus, respectively. The length of oesophagus irradiated was derived from RT isodose data on axial computed tomography images.
Oesophagitis
The occurrence of acute oesophageal toxicity (up to 90 days from the commencement of RT) was documented as part of the original cohort study. Acute oesophagitis was graded using a modified version of the National Cancer Institute Common Toxicity Criteria version 3.0 (NCI CTC v3.0). 21 The development of acute oesophagitis of grade 2 or above at any time within this period was recorded. Grade two oesophagitis was chosen as the cutoff, as it is at this grade or above that nutritional intake is altered according to the NCI CTC v3.0 definition.
Statistical analysis
Data analysis was conducted using SPSS Version 21 (IBM SPSS, Chicago, IL, USA). Descriptive statistics were used to summarise the demographic and medical characteristics of the sample. Univariate logistic regression was used to model the likelihood of ⩾ 5% weight loss by age, oesophagitis (less than grade 2; grade 2 or above), disease stage (early stage, Ia, Ib, IIa, IIb; late stage, IIIa, IIIb, IV), mean oesophageal dose, relative oesophageal volume receiving 20, 30, 40, 50 and 60 Gy and absolute and relative oesophageal length receiving 20, 30, 40, 50 and 60 Gy to the whole and partial circumference. Maximum dose to the oesophagus was highly skewed and not readily transformable, and thus the Mann-Whitney U-test was used to compare differences in maximum dose to the oesophagus between patients with and without ⩾ 5% weight loss. Alpha was set at 0.05 (twotailed) in all analyses. The independent variables that demonstrated significance were all variations measuring the dose to the oesophagus, and the correlations between them were high. In addition, in a sample size of 50, we could only test a single predictor with a medium-sized relationship. Therefore, multivariate analysis was not appropriate. No adjustment was made for multiplicities, as the intent of the analysis was exploratory. A posthoc analysis, using independent sample t-tests, examined differences in demographic (age, disease stage) and medical characteristics (total dose RT received) between patients with and without post-treatment weight data.
RESULTS
Four patients for whom weight was not available at the start or end of RT treatment were excluded, leaving 50 patients for analysis. Patient characteristics are described in Table 1 . A total of 39 patients were treated with radical intent (50 or 60 Gy), and 11 patients were treated with palliative intent (30, 40 or 45 Gy).
Weight loss Weight data were available at a median of 4 (interquartile range (IQR) = 3-5) times per patient. The prevalence of ⩾ 5% weight loss was 22% (n = 11), with a median weight loss within these 11 patients of 9.1% (range = 5.9-22.1%), and it only occurred in patients who received radical treatment with 60 Gy RT over 6 weeks. In 5 (45%) of these 11 patients, this weight loss occurred during RT at a median time point of week 6 of RT. The remaining 6 (55%) patients reached this extent of weight loss following the completion of treatment at a median time point of week 6 post RT completion. Weight data beyond the completion of RT were not available for 76% (n = 38) of the participants. Only one patient received enteral feeding. Post-hoc analysis revealed no significant differences in demographic or medical characteristics between patients who did and did not have post-treatment weight data.
Oesophagitis Assessment of acute oesophageal toxicity was completed a median of 10 times per patient (range = 1-22 times) in the 90 days following commencement of RT. Acute oesophageal toxicity of grade 2 or above occurred in 50% (n = 25) of the participants. The median number of days following the commencement of RT that oesophagitis of grade 2 or above was first and last reported was 30 days (range = 9-64 days) and 38 days (range = 11-64 days), respectively. However, grade 1 oesophagitis may have occurred both earlier and later than this. The association between oesophageal toxicity of grade 2 or above and ⩾ 5% weight loss was not significant (odds ratio = 3.45, 95% confidence interval = 0.79,15.01, P = 0.10). Of the 25 patients in whom oesophageal toxicity of grade 2 or above was reported, the majority (68%, n = 17) did not have ⩾ 5% weight loss. However, of the 11 patients who experienced ⩾ 5% weight loss, the majority (72%, n = 8) were reported to have oesophageal toxicity of grade 2 or above.
Dosimetric factors
Maximum dose to the oesophagus, absolute oesophageal length receiving 40, 50 and 60 Gy to the partial circumference and relative oesophageal length receiving 50 and 60 Gy to the partial circumference were all significantly associated with ⩾ 5% weight loss (Table 2) . Absolute oesophageal length receiving 60 Gy to the partial circumference, however, was more strongly related to ⩾ 5% weight loss than absolute oesophageal length receiving 40 and 50 Gy to the partial circumference. Similarly, relative oesophageal length receiving 60 Gy to the partial circumference was more strongly related to ⩾ 5% weight loss than relative oesophageal length receiving 50 Gy to the partial circumference. The odds of a patient having ⩾ 5% weight loss increases by 32% for each 1 cm increase in the length of the oesophagus receiving 60 Gy to the partial circumference (95% confidence interval = 1.09-1.60, P = 0.005). The median absolute oesophageal length receiving 60 Gy to the partial circumference for those with less than 5% weight loss was 0 cm (IQR = 0-3.8 cm), and the median for those with ⩾ 5% weight loss was 7.2 cm (IQR = 5.5-8.5 cm; Figure 1 ). The odds of a patient having ⩾ 5% weight loss increases by 7% for each 1% increase in the oesophageal length receiving 60 Gy to the partial circumference (95% confidence interval = 1.02-1.11, P = 0.005). The median relative oesophageal length receiving 60 Gy to the partial circumference for those with less than 5% weight loss was 0% (IQR = 0-15.8%), and the median for those with ⩾ 5% weight loss was 30.3% (IQR = 21.6-40%). The same doses to the whole circumference were not associated with loss of weight. The median maximum dose to the oesophagus was significantly greater for patients with clinically significant weight loss (62.2 vs 59.8 Gy, P = 0.046). Tables 2 and 3 outline the median differences and associations with the remaining dosimetric factors between patients who lost ⩾ 5% weight and those who lost less Owing to a skewed distribution for maximum dose to the oesophagus, the Mann-Whitney U-test was calculated to test the difference in medians between patients with and without greater than 5% loss of weight. The bold entries indicate statistically significant results.
than 5% weight. Disease stage and age were not associated with ⩾ 5% weight loss (Table 2) .
DISCUSSION
Maximum dose to the oesophagus, absolute and relative oesophageal length receiving 40 or 50 Gy and absolute oesophageal length receiving 60 Gy to the partial circumference were all significantly associated with clinically significant weight loss in patients with NSCLC. The exploration of RT dosimetric factors associated with clinical outcomes other than treatment toxicities is a new and innovative area of research. The identification of these factors has significant implications for clinical practice. Studies are emerging in patients with head and neck cancer that have identified dosimetric factors associated with poorer swallowing and nutritional outcomes. 13, 22 Data on dosimetric factors associated with weight loss in NSCLC patients treated with RT are vital to facilitate early nutritional intervention.
In this study, the prevalence of clinically significant weight loss was 22%. This is lower than the rates of 33 and 67% that have been reported in patients with head and neck cancer or gastrointestinal cancers. 23 This is most likely owing to the impact of the location of these tumours in the gastrointestinal tract on nutritional intake, although not all the gastrointestinal and head and neck cancer patients in these reported studies were receiving RT treatment. 23 However, the prevalence in the current study still equates to one in five patients with clinically significant weight loss and may be underestimated because of the limited availability of data on weight following the completion of treatment.
Acute oesophageal toxicity of grade 2 or above occurred in half of the study population. Further, the majority of patients with clinically significant weight loss were reported to have oesophageal toxicity of grade 2 or above. Nonetheless, the association between oesophagitis and weight loss was not statistically significant. Both weight loss and the development of oesophagitis tended to occur towards the end or after the completion of RT treatment, indicating that this is an important time to be monitoring and managing treatment toxicities and nutritional issues. 
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A number of dosimetric factors were significantly associated with weight loss. This reflects the findings of the studies investigating dosimetric factors associated with oesophageal toxicity in patients with NSCLC. 17, 19 A recent systematic review confirmed that the volume of the oesophagus receiving 60 Gy is the strongest predictor of oesophagitis. 24 Maximum dose to the oesophagus has been shown to be associated with oesophagitis, 19 and results from this study suggest that it is also significantly associated with weight loss. In contrast, mean oesophageal dose has been associated with oesophagitis in three previous studies, but it was not significantly associated with weight loss in the current study. 19, 25, 26 An interesting finding from this study is the significant association between weight loss and both absolute and relative oesophageal length receiving doses above 40 and 50 Gy, respectively, to the partial circumference. Oesophageal length receiving doses above 40 Gy to the whole circumference has previously been found to be associated with oesophagitis. 18 Our findings suggest that it may not be necessary for the whole circumference of the oesophagus to be treated in order to have an impact on clinical outcomes. This may be related to the narrow width of the oesophagus whereby pain from oesophageal toxicity along one side of the oesophagus is sufficient to affect the passage of food and fluids. Alternatively, the lack of association with the whole circumference may be related to the small sample size.
All patients in this study were receiving cCRT. In a previous study (n = 96), we demonstrated that patients receiving cCRT were more likely to have clinically significant weight loss than those treated with RT alone (40% vs 0%, Po 0.001). In the same study, a comparison of cisplatin-and carboplatin-based regimens, there was no significant association between the type of chemotherapy and weight loss. However, there remained 60% of patients receiving cCRT who did not have clinically significant weight loss. 27 The current study demonstrates that dosimetric factors provide valuable information to further delineate those cCRT patients who are most at risk of weight loss.
Oesophageal involvement in the RT field is difficult to avoid owing to the central location of many lung tumours or the presence of mediastinal nodal disease. During RT planning, the radiation dose to the oesophagus cannot be minimised at the expense of providing the optimal dose to the tumour. However, compared with the 3DCRT techniques used for the treatment of patients in this trial, more sophisticated methods of RT planning including Intensity Modulated RT offer greater potential to spare the oesophagus from such isotoxic doses. 28 Overall, however, it is likely that oesophagitis will continue to be an ongoing toxicity associated with thoracic RT. Understanding the dosimetric factors associated with weight loss enables the identification of patients at nutritional risk at the time of RT planning and allows the subsequent provision of timely and appropriate nutritional intervention and monitoring. This study suggests that patients receiving 60 Gy to the partial oesophageal circumference should be closely monitored for weight loss, with the risk of weight loss increasing as longer lengths of the oesophagus are treated at this dose. Further investigation is required to determine a cutoff point for the length of the oesophagus treated with 60 Gy that confers a high risk of weight loss.
Improving the knowledge of factors associated with clinically significant weight loss, in conjunction with established factors associated with oesophagitis, could provide an impetus to utilise enteral nutrition more effectively in lung cancer patients treated with RT. Only one patient in our study received enteral nutrition, which may be owing to a lack of standardised enteral feeding protocols for patients with lung cancer. The use of enteral nutrition is common in patients with head and neck cancer, and the factors associated with a high risk of requiring enteral nutrition are well established. 12, 29 A number of protocols exist for head and neck cancer patients, using the known high-risk factors to guide the appropriate use of enteral nutrition. 30, 31 Current guidelines recommend that routine enteral nutrition is not indicated during radiation therapy. 32 Understanding the patients at high risk of requiring enteral nutrition is an area that requires further development and investigation in patients receiving RT for lung cancer.
Analysis of the results from the current study are limited by the small sample size, whereby running a multivariate analysis was inappropriate, and therefore the results should be considered preliminary and require validation in a larger prospective cohort. Although demographic and clinical characteristics did not differ at baseline, the lack of post-treatment weight data may have resulted in underestimating the prevalence of weight loss. Data on weight loss or nutritional status before the commencement of RT were not available, and therefore the impact of these factors could not be explored. However, despite these limitations, significant associations between clinically significant weight loss and multiple dosimetric factors were found and reflect the associations that have been found in studies investigating dosimetric factors associated with oesophagitis.
This study showed that multiple dosimetric factors are associated with clinically significant weight loss in lung cancer patients treated with cCRT. Of the dosimetric factors that were significantly related to ⩾ 5% weight loss, absolute and relative length of the oesophagus receiving 60 Gy to the partial circumference were more strongly related. The identification of robust predictors of clinically significant weight loss may assist clinicians in targeting nutritional interventions towards the patients at highest nutritional risk.
